Natural hormone replacement therapy with a functioning ovary after the menopause: dream or reality?
Publication date: Available online 30 June 2018 Source:Reproductive BioMedicine Online Author(s): Jacques Donnez, Marie-Madeleine Dolmans At the dawn of humanity, it was rare to live beyond the age of 35 years, so the ovary was intended to function for a woman's entire life. Nowadays, it is not unusual for women to live into their 80s. This means that many of them spend 30–40% of their lives in the menopause at increased risk of various conditions associated with an absence of oestrogens (cardiovascular disease, bone mineral density loss). Reimplantation of frozen–thawed ovarian tissue is able to restore long-term ovarian endocrine function that can persist for more than 7 years (12 years if the procedure is repeated). If ovarian tissue reimplantation is capable of restoring ovarian activity after menopause induced by chemotherapy, radiotherapy, surgery, or a combination of all three, why not propose it to recover sex steroid secretion after natural menopause and prevent menopause-related conditions in the ageing population? In this application, the graft site could be outside the pelvic cavity, e.g., forearm or rectus muscle. Could ovarian tissue freezing at a young age followed by reimplantation upon reaching menopause be the anti-ageing therapy of the future? Sufficient existing evidence now surely merits serious debate.
This essay summarizes current evidence on the relative contributions of chronologic and reproductive aging to women's cardiovascular, cardiometabolic, and cognitive health.Menopause
Judy Bolton helps demystify the complex bioactivity of hops to benefit women ’s health
Thank you for the opportunity to reply to the Letter of Dr. Lentle and colleagues regarding our article “Identification of asymptomatic frailty vertebral fractures in post-menopausal women” .
Re: Pizzato S, Trevisan C, Lucato P, et al. Identification of asymptomatic frailty vertebral fractures in post-menopausal women.
AbstractPurpose of ReviewThe purpose of this article is to review the available data regarding the application and therapeutic outcomes of laser therapy for the treatment of genitourinary syndrome of menopause (GSM).Recent FindingsThere have been several studies regarding the use of laser therapy for the treatment of GSM. Most of these studies show a trend toward safe and effective treatment in the short term (less than or equal to 12 weeks). However, these studies are lacking in randomization, blinding, placebo, and comparison groups.SummaryAlthough laser therapy for the treatment of the symptoms of GSM appears prom...
Acupuncture has been used for women during menopausal transition, but evidence is limited.
This study investigated the effect of ...
CONCLUSION: These findings suggest that ERβ alternative splicing and altered responses in the regulatory system for serotonin may mediate the antidepressant efficacy of ET associated with the timing of therapy initiation. It is likely that ERβ-specific ligands would be effective estrogen-based antidepressants late after the onset of menopause. PMID: 30106359 [PubMed - as supplied by publisher]
Conditions: Menopause Surgical; Estrogen Deficiency; Adiposity Intervention: Procedure: Bilateral Oophorectomy Surgery Sponsors: Pennington Biomedical Research Center; Louisiana Clinical and Translational Science Center Not yet recruiting
Â Back in February, MD+DI got the low down from an obstetrics and gynecologist specialist in Lubbock, TX on a new vaginal rejuvenation device that her patients have been raving about. Â Now it seems the manufacturer of that particular device, along with other companies selling laser- or energy-based devices for vaginal rejuvenation failed to get FDA's blessing. "We've recentlyÂ become aware of a growing number of manufacturers marketing 'vaginal rejuvenation' devices to women and claiming these procedures will treat conditions and symptoms related to menopause, urinary incontinence, or...